In this interview, Martin Dietrich, MD, PhD, thoracic oncologist with The US Oncology Network and Cancer Care Centers of Brevard, discusses durvalumab’s transformative impact on NSCLC treatment ...

“Our findings suggest that durvalumab did not improve outcomes compared with cetuximab in patients with HNSCC with contraindications to cisplatin,” the authors concluded. “These findings are ...

Immune-mediated rash or dermatitis occurred in 1.8% (34/ ... Europe and Asia. IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction ...

All the patients were diagnosed with advanced BTCs. The primary objective was to assess median overall survival (mOS) with the use of durvalumab in combination with chemotherapy backbone. The patient ...

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer Based on ADRIATIC Phase III trial results which showed a 27 ...

WILMINGTON, Del., December 05, 2024--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung ...

23 December 2024 As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Durvalumab with tremelimumab for treating limited-stage ...

However, there is currently no consensus on the standard of care for this population. Durvalumab, an immune checkpoint inhibitor, has shown promise for treating a wide range of cancers ...

Opens in a new tab or window The FDA expanded the indications for the immune checkpoint inhibitor durvalumab (Imfinzi) to include limited-stage small cell lung cancer (SCLC). Approval stipulates ...